Regulation
The ACCC’s News Media Bargaining Code: Experimenting with “Decentralized Regulation” of Dominant Digital Platforms
The Australian Competition and Consumer Commission recently proposed a mandatory bargaining code to govern negotiations between digital platforms like Google and Facebook and publishers...
Self-Favoring in the Digital Economy and the Role of Antitrust
At the moment, the strategy of the major tech platforms seems to be to deny any bias and malicious self-favoring. The facts, however, do...
Special Interests Hide Behind Regulatory Myths
Three myths about federal regulation help prevent much of the public, and many experts, from realizing how many regulations serve to promote special interests.
Years...
The House’s Big Tech Hearing: Break Ups Large and Small?
Last week’s epic House hearing on online platforms raised many issues, chief among which was the question who gets to operate at scale.
Last week’s...
Top 10 Admissions from Tech CEOs Secured at the Antitrust Hearing
This week’s Congressional hearing produced evidence of anticompetitive conduct that state attorneys general and private enforcers can use to pursue the dominant platforms under...
More and More Employers Are Spying on Workers Online. Federal Regulators Are Okay With It
Employers today have numerous tools at their disposal to monitor workers’ behavior and communications. Outdated federal regulations and an administration that prioritizes employers’ interests...
What Congress Should Ask Big Tech CEOs
This week, the House Committee on the Judiciary will hold a hearing on digital platforms and market power, during which members will get to question...
The EU’s Attempt at Updating Antitrust Market Definition for the Digital Age
The rise of digital platforms has upended markets and the very act of market definition—the basic unit of antitrust analysis. With the review of...
Was the 2017 FCC Spectrum Auction a Success—or a Disappointing Failure?
In a post published on his company’s website, Stanford professor Paul Milgrom responded to the recent ProMarket pieces by Glen Weyl and Stefano Feltri...
Paid to Show the Drug Works: Why “Blind” Clinical Trials for New Drugs are Far Less Blind Than They Should Be
New research shows that physicians in industry-sponsored trials are more captured by pharmaceutical companies than physicians in unsponsored ones.
Economists love health care because it...
